首页> 外文期刊>Evidence-based complementary and alternative medicine: eCAM >Treatment Effects of Xuebijing Injection in Severe Septic Patients with Disseminated Intravascular Coagulation
【24h】

Treatment Effects of Xuebijing Injection in Severe Septic Patients with Disseminated Intravascular Coagulation

机译:血必净注射液对严重脓毒症弥散性血管内凝血的治疗效果

获取原文
           

摘要

The treatment effects of Xuebijing (XBJ) injection in severe septic patients with disseminated intravascular coagulation (DIC) were investigated in this study. 171 severe septic patients with DIC were divided into the control group (n=83) or intervention group (n=88). Routine therapies were administered in both groups, and XBJ injection was administered additionally in the intervention group. Incidence of DIC, clinical severity scores, and coagulation parameters at 7 days after administration of XBJ injection were compared between the two groups, and short-term prognosis was evaluated by 28-day mortality. Compared with the control group, incidence of DIC in the intervention group was significantly lower at 7 days after administration of XBJ injection (P<0.001). In addition, differences of platelet count and prothrombin time were significantly greater in the intervention group than in the control group (Pall <0.05), and similar results were also found for differences of the Mortality in Emergency Department Sepsis score and Acute Physiology and Chronic Health Evaluation II score (Pall <0.05). Furthermore, 28-day mortality was significantly lower in the intervention group (P=0.034). These results demonstrate that XBJ injection can effectively treat DIC caused by severe sepsis and improve short-term prognosis of severe septic patients with DIC.
机译:本研究探讨了血必净(XBJ)注射液对严重脓毒症弥散性血管内凝血(DIC)患者的治疗效果。将171例重度DIC败血症患者分为对照组(n = 83)或干预组(n = 88)。两组均进行常规治疗,干预组另外进行XBJ注射。比较两组在XBJ注射后7天的DIC发生率,临床严重程度评分和凝血参数,并通过28天死亡率评估短期预后。与对照组相比,干预组在注射XBJ后7天的DIC发生率显着降低(P <0.001)。此外,干预组的血小板计数和凝血酶原时间差异明显大于对照组(Pall <0.05),急诊败血症死亡率和急性生理与慢性病的死亡率差异也相似。评估II评分(Pall <0.05)。此外,干预组的28天死亡率显着降低(P = 0.034)。这些结果表明,XBJ注射液可有效治疗严重败血症引起的DIC,并改善重度脓毒症患者的短期预后。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号